Invitrogen™ Adalimumab Recombinant Human Monoclonal Antibody (D2E7 (Adalimumab))

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA548047

Catalog No. PIMA548047

Description

Specificity: Binds to soluble TNF-alpha, but not to lymphotoxin (TNF beta).

Adalimumab (Humira) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab binds to the TNF alpha (tumor necrosis factor-alpha), and blocks its interaction with TNF alpha receptors, reducing the inflammatory response of autoimmune diseases.

Specifications

• Antigen: Adalimumab
• Classification: Recombinant Monoclonal
• Concentration: 1 mg/mL
• Formulation: PBS with 0.02% ProClin 300
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Target Species: Human, Mouse
• Product Type: Antibody
• Isotype: IgG1 κ

• Applications: ELISA, Inhibition Assays, Immunohistochemistry, Immunocytochemistry
• Clone: D2E7 (Adalimumab)
• Conjugate: Unconjugated
• Gene Alias: D2E7; Humira
• Immunogen: This antibody was generated by affinity maturation from the 2SD4 scFv, which in turn was selected on human TNF alpha by guided phage-display technology, using the murine anti-hTNF alpha antibody Mab32 as a template.
• Quantity: 200 μg
• Primary or Secondary: Primary
• Content And Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
• Form: Liquid